Compare Abbott Laboratories (ABT) vs Ares Capital Corporation (ARCC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Ares Capital Corporation — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while Ares Capital Corporation trades at $18.35 (market cap $13.26B). The key difference: Abbott Laboratories is far larger — about 12.6× Ares Capital Corporation's market cap, and Ares Capital Corporation pays the higher dividend (10.4%). Which is the better fit depends on your goals.
| ABT | ARCC | |
|---|---|---|
Market Cap | $166.94B | $13.26B |
Sector | Health | Financials |
52-Week High | $136.62 | $23.25 |
52-Week Low | $82.57 | $17.45 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 10.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ARCC trades at $18.47, down 1.39% on the day, near its consensus low price target of $18.50. The stock shows neutral technical signals with mixed moving averages and oscillators. Recent quarterly EPS results have missed expectations, though the company maintains a high net income margin of 84.5%. A dividend of $0.48 is scheduled for payment on June 30, 2026, supporting income-focused strategies.
Outlook remains cautiously optimistic given strong analyst support (24 Buy, 8 Hold) and a $20.58 consensus target implying ~11% upside. Risks include earnings misses and revenue declines from $1.7B in 2024 to a projected $1.4B in 2026. The stock's P/E of 11.39 and P/B of 0.95 suggest reasonable valuation amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →
